General Information of the Compound
Compound ID |
CP0141502
|
||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Compound Name |
4-[2-(5-methyl-1-naphthalen-2-ylpyrazol-3-yl)oxyethyl]morpholine
Show/Hide
|
||||||||||||||||||
Synonyms |
A12504
AKOS026750239
AOB87704
BCP08990
BDBM50396352
CS-2187
DA-40938
E-52862
E52862
FT-0700391
GTPL10431
HY-18099
MCULE-6623106441
MR309
NCGC00371119-04
Q7388203
S1RA
SB17181
UNII-ZW18DSD1H4
ZINC95000617
ZW18DSD1H4
compound 28 [PMID: 22784008]
s6754
sigma 1 receptor antagonist (S1RA)
Show/Hide
|
||||||||||||||||||
Structure |
|
||||||||||||||||||
Formula |
C20H23N3O2
|
||||||||||||||||||
Molecular Weight |
337.423
|
||||||||||||||||||
Canonical SMILES |
Cc1cc(OCCN2CCOCC2)nn1-c1ccc2ccccc2c1
Show/Hide
|
||||||||||||||||||
InChI |
InChI=1S/C20H23N3O2/c1-16-14-20(25-13-10-22-8-11-24-12-9-22)21-23(16)19-7-6-17-4-2-3-5-18(17)15-19/h2-7,14-15H,8-13H2,1H3
Show/Hide
|
||||||||||||||||||
InChIKey |
DGPGXHRHNRYVDH-UHFFFAOYSA-N
|
||||||||||||||||||
Physicochemical Property |
"RO5" indicates the cutoff set by lipinski's rule of five: (1) Molecular weight less than 500 Dalton; (2) xlogp less than 5; (3) No more than 5 hbonddonor (Hydrogen Bond Donor Count); (4) No more than 10 hbondacc (Hydrogen Bond Acceptor Count); (5) No more than 10 rotbonds (Rotatable Bond Count). Show/Hide
|
||||||||||||||||||
Click to Show/Hide the External Link(s) of This Compound | |||||||||||||||||||
PubChem ID | |||||||||||||||||||
ChEMBL ID | |||||||||||||||||||
DrugBank ID |
Map of Molecular Bioactivity Related to the Compound
Map of Molecular Bioactivity Related to the Compound Compound Cell Line Protein Bioactivity Value: <= 0.1 μM > 0.1 μM and <= 10 μM > 10 μM Imprecise Activity |
|
---|
Table of Molecular Bioactivities Related to the Compound
Protein ID: PT01515, Mu-type opioid receptor
Protein ID: PT00897, Potassium voltage-gated channel subfamily H member 2
Protein ID: PT01509, Sigma non-opioid intracellular receptor 1
Clinical Information about the Compound